Novo Nordisk: Final approval for Tresiba and Ryzodeg in Europe - progressive launch expected

NEUTRAL, Fair Value DKK1000 (+1%)

News published on January Tuesday 22, 2013
Share on
Yesterday Novo-Nordisk received the final nod for the approval of its new-generation insulins Tresiba (long-acting) and Ryzodeg (mixed insulin) from the European Commission. It received a positive recommendation for both drugs in October 2012 from the CHMP.

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities